BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 34540237)

  • 21. SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study.
    Hill JA; Martens MJ; Young JH; Bhavsar K; Kou J; Chen M; Lee LW; Baluch A; Dhodapkar MV; Nakamura R; Peyton K; Shahid Z; Armistead P; Westervelt P; McCarty J; McGuirk J; Hamadani M; DeWolf S; Hosszu K; Sharon E; Spahn A; Toor AA; Waldvogel S; Greenberger LM; Auletta JJ; Horowitz MM; Riches ML; Perales MA
    EClinicalMedicine; 2023 May; 59():101983. PubMed ID: 37128256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the ventricular assist device programme in the UK.
    Sharples L; Buxton M; Caine N; Cafferty F; Demiris N; Dyer M; Freeman C
    Health Technol Assess; 2006 Nov; 10(48):1-119, iii-iv. PubMed ID: 17134596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Donor considerations in pediatric kidney transplantation.
    Chandar J; Chen L; Defreitas M; Ciancio G; Burke G
    Pediatr Nephrol; 2021 Feb; 36(2):245-257. PubMed ID: 31932959
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
    Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
    Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risks and Benefits of Kidney Transplantation during the COVID-19 Pandemic: Transplant or Not Transplant?
    Ajaimy M; Liriano-Ward L; Graham JA; Akalin E
    Kidney360; 2021 Jul; 2(7):1179-1187. PubMed ID: 35368354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SARS-COV-2 vaccine responses in renal patient populations.
    Smith RM; Cooper DJ; Doffinger R; Stacey H; Al-Mohammad A; Goodfellow I; Baker S; Lear S; Hosmilo M; Pritchard N; Torpey N; Jayne D; Yiu V; Chalisey A; Lee J; Vilnar E; Cheung CK; Jones RB
    BMC Nephrol; 2022 May; 23(1):199. PubMed ID: 35641961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predicting 3-Year Survival in Patients Receiving Maintenance Dialysis: An External Validation of iChoose Kidney in Ontario, Canada.
    Tan VS; Garg AX; McArthur E; Patzer RE; Gander J; Roshanov P; Kim SJ; Knoll GA; Yohanna S; McCallum MK; Naylor KL
    Can J Kidney Health Dis; 2018; 5():2054358118799693. PubMed ID: 30302267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Humoral and cellular immune response and the safety of third SARS-CoV-2 mRNA vaccine with longer interval after the second vaccination in kidney transplant recipients.
    Takai S; Nishida H; Ito H; Fukuhara H; Nawano T; Narisawa T; Kanno H; Yagi M; Yamagishi A; Sakurai T; Naito S; Kato T; Morikane K; Tsuchiya N
    Front Immunol; 2022; 13():1050211. PubMed ID: 36532067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kidney Transplantation in Patients With the History of SARS-CoV-2 Infection.
    Juric I; Katalinic L; Furic-Cunko V; Basic-Jukic N
    Transplant Proc; 2022 Dec; 54(10):2673-2676. PubMed ID: 36184341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative Analysis of SARS-CoV-2 Antibody Levels in Cancer Patients Post Three Doses of Immunization and Prior to Breakthrough COVID-19 Infections.
    Macrae K; Martinez-Cajas J; Bessai K; Abdulhamed A; Gong Y
    Curr Oncol; 2022 Sep; 29(10):7059-7071. PubMed ID: 36290831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serological Response and Clinical Protection of Anti-SARS-CoV-2 Vaccination and the Role of Immunosuppressive Drugs in a Cohort of Kidney Transplant Patients.
    Biagio P; Rosa C; Nicola SM; Fabrizio S; Amerigo P; Giulia Z; Riccardo S; Riccardo V; Paolo R; Lorenzo S; Ivan G; Federico Ii Covid Team
    Viruses; 2022 Sep; 14(9):. PubMed ID: 36146758
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluating the antibody response to SARS-COV-2 vaccination amongst kidney transplant recipients at a single nephrology centre.
    Chukwu CA; Mahmood K; Elmakki S; Gorton J; Kalra PA; Poulikakos D; Middleton R
    PLoS One; 2022; 17(3):e0265130. PubMed ID: 35271655
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Humoral immunity against SARS-CoV-2 variants including omicron in solid organ transplant recipients after three doses of a COVID-19 mRNA vaccine.
    Saharia KK; Husson JS; Niederhaus SV; Iraguha T; Avila SV; Yoo YJ; Hardy NM; Fan X; Omili D; Crane A; Carrier A; Xie WY; Vander Mause E; Hankey K; Bauman S; Lesho P; Mannuel HD; Ahuja A; Mathew M; Avruch J; Baddley J; Goloubeva O; Shetty K; Dahiya S; Rapoport AP; Luetkens T; Atanackovic D
    Clin Transl Immunology; 2022; 11(5):e1391. PubMed ID: 35505864
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Surgical outcomes after pediatric kidney transplantation at the University of Heidelberg.
    Mehrabi A; Golriz M; Khajeh E; Ghamarnejad O; Kulu Y; Wiesel M; Müller T; Majlesara A; Schmitt CP; Tönshoff B
    J Pediatr Urol; 2019 May; 15(3):221.e1-221.e8. PubMed ID: 30795985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluating clinical effectiveness of SARS-CoV-2 vaccine in solid organ transplant recipients: A propensity score matched analysis.
    Tucker M; Azar MM; Cohen E; Gan G; Deng Y; Foppiano Palacios C; Malinis M
    Transpl Infect Dis; 2022 Aug; 24(4):e13876. PubMed ID: 35684932
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of Using Kidneys From HCV-Viremic Donors for Transplantation Into HCV-Uninfected Recipients.
    Eckman MH; Woodle ES; Thakar CV; Alloway RR; Sherman KE
    Am J Kidney Dis; 2020 Jun; 75(6):857-867. PubMed ID: 32081494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of booster vaccination against SARS-CoV-2 in dialysis and renal transplant patients: systematic review and meta-analysis.
    Taheri S
    Int Urol Nephrol; 2023 Apr; 55(4):791-802. PubMed ID: 36723829
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity.
    Bowman KA; Stein D; Shin S; Ferbas KG; Tobin NH; Mann C; Fischinger S; Ollmann Saphire E; Lauffenburger D; Rimoin AW; Aldrovandi G; Alter G
    mBio; 2022 Oct; 13(5):e0164722. PubMed ID: 36000735
    [TBL] [Abstract][Full Text] [Related]  

  • 39. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status.
    Neidleman J; Luo X; McGregor M; Xie G; Murray V; Greene WC; Lee SA; Roan NR
    Elife; 2021 Oct; 10():. PubMed ID: 34636722
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.